Sigma Planning Corp Sells 1,923 Shares of Novo Nordisk A/S (NYSE:NVO)

Sigma Planning Corp trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO) by 16.6% in the fourth quarter, Holdings Channel reports. The fund owned 9,637 shares of the company’s stock after selling 1,923 shares during the quarter. Sigma Planning Corp’s holdings in Novo Nordisk A/S were worth $997,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of NVO. Riggs Asset Managment Co. Inc. acquired a new position in shares of Novo Nordisk A/S during the fourth quarter valued at about $4,794,000. Criterion Capital Advisors LLC acquired a new position in shares of Novo Nordisk A/S during the fourth quarter valued at about $735,000. Tradewinds Capital Management LLC raised its position in shares of Novo Nordisk A/S by 2.0% during the fourth quarter. Tradewinds Capital Management LLC now owns 4,955 shares of the company’s stock valued at $513,000 after buying an additional 95 shares during the last quarter. Signaturefd LLC raised its position in shares of Novo Nordisk A/S by 3.2% during the fourth quarter. Signaturefd LLC now owns 73,139 shares of the company’s stock valued at $7,566,000 after buying an additional 2,267 shares during the last quarter. Finally, Pathway Financial Advisors LLC acquired a new position in shares of Novo Nordisk A/S during the fourth quarter valued at about $269,000. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $128.62 on Wednesday. Novo Nordisk A/S has a 1 year low of $75.56 and a 1 year high of $138.28. The firm has a 50 day moving average of $126.66 and a 200-day moving average of $111.54. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $577.19 billion, a P/E ratio of 47.55, a price-to-earnings-growth ratio of 2.09 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. The company had revenue of $9.51 billion during the quarter, compared to analysts’ expectations of $9.14 billion. As a group, sell-side analysts anticipate that Novo Nordisk A/S will post 3.32 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th were paid a $0.664 dividend. The ex-dividend date was Friday, March 22nd. This represents a dividend yield of 0.9%. This is a boost from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. Novo Nordisk A/S’s payout ratio is 49.17%.

Analysts Set New Price Targets

NVO has been the subject of a number of analyst reports. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price target for the company. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. BMO Capital Markets initiated coverage on shares of Novo Nordisk A/S in a research note on Friday, April 12th. They set an “outperform” rating and a $163.00 price target for the company. Finally, UBS Group initiated coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 16th. They set a “neutral” rating for the company. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $133.60.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.